0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Transdermal Nicotine for Smoking Cessation:  Six-Month Results From Two Multicenter Controlled Clinical Trials

Arden Christen, DDS; Bradley Beiswanger, DDS; Melissa Mau, MS; Cheryl Walker; Dorothy Hatsukami, PhD; Sharon Allen, PhD; Marguerite Huber, NP; Joni Jensen; Stephen Rennard, MD; David Daughton, MS; Ronald Cheney, PA-C; Kathleen Hatlelid, PA-C; Austin Thompson, MD; Edward Lichtenstein, PhD; Anthony Biglan, PhD; Linda Ochs, MS; Scott Heatley, PhD; Lawrence Repsher, MD; William Schones; Dara Stlllman, CRTT; Cheryl Casey, CRTT; Bonnie Poole, RRT; Jennifer Leitch, RN; Stephen Fortmann, MD; Joel Killen, PhD; Mark Hansen; L. Rasenick Douss; John Hughes, MD; William Valliere; Laura Solomon, PhD; William Wadland, MD; Elbert Glover, PhD; Penny Glover, MEd; Donna Causey, MD; Mark Knowles, PhD; Katherine Voss-Roberts, MS; Della Prather, MA; Nancy Trunnell; Diane Moos; Clyde Rolf, MD; Robert Nowak, PhD; Phillip Ackerman, MS; Neil Malone, MA
JAMA. 1991;266(22):3133-3138. doi:10.1001/jama.1991.03470220049025.
Text Size: A A A
Published online

Objective.  —To evaluate the efficacy of a new transdermal nicotine system for smoking cessation.

Design.  —Two 6-week, randomized, double-blind, placebo-controlled, parallel group trials were conducted. Successful abstainers from both trials enrolled in a third trial for blinded downtitration from medications (6 weeks) and subsequent off-drug follow-up (12 weeks).

Setting.  —Nine outpatient clinics specializing in the treatment of smoking cessation.

Patients.  —Healthy volunteers who smoked one or more packs of cigarettes daily and wanted to participate in a smoking cessation program.

Intervention.  —Patients were randomly assigned to a transdermal nicotine system delivering nicotine at rates of 21,14, or 7 mg (in trial 1 only) over 24 hours or to placebo. Group counseling sessions were provided to all participants.

Main Outcome Measure.  —Rates of continuous smoking abstinence were determined during 6 weeks of full-dose treatment, a 6-week weaning period (through week 12), and a 3-month follow-up receiving no therapy (through week 24). Abstinence was defined by patient diary reports of no smoking during the designated periods, confirmed by expired-breath carbon monoxide levels of 8 ppm or lower.

Results.  —The centers enrolled 935 patients. Cessation rates during the last 4 weeks of the two 6-week trials (pooled data) were 61%, 48%, and 27% for 21-and 14-mg transdermal nicotine and placebo, respectively (P≤.001 for each active treatment vs placebo). Six-month abstinence rates for 21-mg transdermal nicotine and placebo were 26% and 12%, respectively (P≤.001). All transdermal nicotine doses significantly decreased the severity of nicotine withdrawal symptoms and significantly reduced cigarette use by patients who did not stop smoking. Compliance was excellent, and no serious systemic adverse effects were reported.

Conclusions.  —Transdermal nicotine systems show considerable promise as an aid to smoking cessation.(JAMA. 1991;266:3133-3138)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();